Loading institutional data...
Loading institutional data...
No institutional (13F) filings cover this company, so the Overview and 13F tabs are thin. Everything drawn from its SEC filings is here.
Loading snapshot...
Loading financials...
Loading valuation...
Loading analysis...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Ranked against 16 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-09-30.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMRN | $509M | — | — | 2.4× | -6.5% | 56.6% | -18.2% | -8.4% | -8.4% | — | 9 |
| GYRE | $484M | 228.0× | 31.1× | 4.2× | 10.2% | 95.4% | 8.5% | 15.8% | 15.8% | -3.5× | 7 |
| SVA | $465M | — | — | 1.2× | 6.8% | 67.9% | -51.5% | -4.5% | -4.0% | — | 2 |
| CRMD | $447M | 2.8× | 2.0× | 1.4× | 617% | 88.5% | 52.3% | 40.2% | 40.2% | -1.0× | 24 |
| VREOF | $385M | — | 18.8× | 1.4× | 170% | 47.3% | -25.3% | -22.2% | -22.2% | -6.8× | — |
| EBS | $349M | 7.3× | 3.6× | 0.5× | -28.8% | 56.1% | 7.1% | 10.1% | 4.8% | 1.9× | 29 |
| QTTB | $265M | 3.7× | 12.6× | 4.9× | — | — | 55.5% | 71.0% | 71.0% | -2.8× | 3 |
| ELTP | $248M | 7.7× | 4.3× | 1.7× | 77.1% | 50.4% | 30.1% | 45.4% | 45.4% | -0.6× | — |
| SIGA | $218M | 9.5× | 2.6× | 2.3× | -31.8% | 68.6% | 24.6% | 11.7% | 11.7% | -6.4× | 25 |
| PYXS | $216M | — | — | 15.6× | -14.2% | 82.8% | -575% | -149% | -149% | — | 10 |
| NATR | $216M | 11.6× | 3.1× | 0.5× | 5.7% | 72.4% | 4.1% | 12.1% | 12.1% | -2.4× | 19 |
| AKBA | $196M | — | 2.4× | 0.8× | 47.5% | 83.3% | -2.3% | -16.4% | -6.6% | -5.5× | 27 |
| WHWK | $185M | — | — | 25.9× | -72.5% | 89.4% | -288% | -15.1% | -15.1% | — | 10 |
| MGNX | $153M | — | — | 1.0× | -0.3% | 100% | -49.9% | -134% | -134% | — | 18 |
| DERM | $146M | — | — | 2.4× | 10.2% | 66.2% | -18.5% | -35.9% | -20.0% | — | 4 |
| BGM | $127M | — | — | 3.4× | 51.1% | 16.6% | -52.6% | -5.1% | -5.1% | — | — |
| UPC | $7M | — | — | — | -22.4% | 35.3% | -20.6% | -6.5% | -5.8% | — | — |
Peers = companies sharing UPC's sector (Pharmaceutical Preparations) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$5.32B FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 7 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -6%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 7 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
EOD close · as of 2026-10-30
How a revenue dollar becomes profit — FY2025
Dividends and buybacks are cash paid out, shown here against the same year's profit for scale — not funded from it.
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $17.86B 100.0% | $23.02B 100.0% | $32.31B 100.0% | $40.1M 100.0% | $48.0M 100.0% | $30.7M 100.0% | $33.2M 100.0% |
| Cost of Revenue | $11.56B 64.7% | $16.95B 73.6% | $21.99B 68.1% | $18.3M 45.5% | $22.7M 47.2% | $16.6M 54.1% | $19.8M 59.7% |
| Gross Profit | $6.30B 35.3% | $6.07B 26.4% | $10.32B 31.9% | $21.9M 54.5% | $25.3M 52.8% | $14.1M 45.9% | $13.4M 40.3% |
| Research & Development | $671.8M 3.8% | $3.03B 13.2% | $4.86B 15.0% | $7.6M 19.0% | $5.5M 11.4% | $583K 1.9% | $618K 1.9% |
| Selling, General & Admin | $3.75B 21.0% | $2.89B 12.6% | $2.64B 8.2% | $2.2M 5.4% | $3.3M 6.9% | $1.7M 5.5% | $1.5M 4.4% |
| Total Operating Expenses | $9.22B 51.6% | $14.09B 61.2% | $14.28B 44.2% | $28.9M 72.0% | $11.7M 24.5% | $3.8M 12.5% | $3.7M 11.0% |
| Operating Income | -$2.92B -16.3% | -$8.02B -34.8% | -$3.97B -12.3% | -$7.0M -17.5% | $13.6M 28.3% | $10.3M 33.4% | $9.8M 29.4% |
| Interest Expense | $289.4M 1.6% | $304.5M 1.3% | $190.2M 0.6% | $162K 0.4% | $102K 0.2% | $124K 0.4% | $129K 0.4% |
| Other Income (Expense), net | -$756.1M -4.2% | -$100.8M -0.4% | -$361.3M -1.1% | -$75K -0.2% | $88K 0.2% | -$151K -0.5% | -$100K -0.3% |
| Pretax Income | -$3.67B -20.6% | -$8.12B -35.3% | -$4.33B -13.4% | -$7.1M -17.7% | $13.7M 28.5% | $10.1M 32.9% | $9.7M 29.0% |
| Income Tax Expense | — | $606.7M 2.6% | $2.25B 7.0% | $815K 2.0% | $2.4M 4.9% | $2.5M 8.3% | $2.1M 6.3% |
| Net Income | -$3.67B -20.6% | -$8.73B -37.9% | -$6.58B -20.4% | -$7.9M -19.7% | $11.3M 23.6% | $7.6M 24.6% | $7.6M 22.7% |
| Per Share | |||||||
| EPS (Basic) | -$8.06 | -$626.96 | -$1089.21 | -$1309.11 | $3.58 | $0.47 | — |
| EPS (Diluted) | -$8.06 | -$626.96 | -$1089.21 | -$1309.11 | $3.58 | $0.47 | — |
| Weighted Avg Shares (Basic) | 456K | 14K | 6K | 6K | 3.2M | 16.0M | — |
| Weighted Avg Shares (Diluted) | 456K | 14K | 6K | 6K | 3.2M | 16.0M | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
How much the company owes, how it's trended, and how comfortably it's serviced.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~4.0% on $7.15B of debt.
Cash of $33.59B fully covers short-term debt of $7.15B.
Mostly short-term debt (balance-sheet current vs non-current split). A year-by-year maturity schedule wasn't disclosed for this issuer.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
A reverse discounted cash flow is not shown for a company with no positive EBITDA.
No positive EBITDA in the recent record, so there is no return on capital to compare against its cost.
Classified from the filings: EBITDA negative in each of the last 2 years.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-10-30
Where each multiple sits in its own 5-yr range
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 5-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
ROE -7% against ROIC -6% — -1% of the return on equity comes from leverage and buybacks rather than from the operating business.
What the company owes vs. what it holds
This shows debt/cash structure and net leverage. The year-by-year maturity schedule is on the Debt & Leverage tab.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 2.8× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cost of Revenue | 59.7 | 54.1 | 47.2 | 45.5 | 68.1 | 73.6 | 64.7 |
| Gross Profit | 40.3 | 45.9 | 52.8 | 54.5 | 31.9 | 26.4 | 35.3 |
| R&D | 1.9 | 1.9 | 11.4 | 19.0 | 15.0 | 13.2 | 3.8 |
| SG&A | 4.4 | 5.5 | 6.9 | 5.4 | 8.2 | 12.6 | 21.0 |
| Operating Income | 29.4 | 33.4 | 28.3 | -17.5 | -12.3 | -34.8 | -16.3 |
| Income Tax | 6.3 | 8.3 | 4.9 | 2.0 | 7.0 | 2.6 | — |
| Net Income | 22.7 | 24.6 | 23.6 | -19.7 | -20.4 | -37.9 | -20.6 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on UPC: price, valuation and headline fundamentals from SEC filings. The four questions at the top of the page are where the judgements live.
No positive operating income in the last three years, so there is no return on capital to compare against its cost.
| Fiscal year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY2019 | 40.3% | 29.4% | 22.7% |
| FY2020 | 45.9% | 33.4% | 24.6% |
| FY2021 | 52.8% | 28.3% | 23.6% |
| FY2022 | 54.5% | -17.5% | -19.7% |
| FY2023 | 31.9% | -12.3% | -20.4% |
| FY2024 | 26.4% | -34.8% | -37.9% |
| FY2025 | 35.3% | -16.3% | -20.6% |
No material counter-signal in the checked set: ROIC vs WACC spread, 5-year spread history, gross margin trend, operating margin trend, net margin against 3 years ago, revenue growth, ROIC ex-goodwill gap.
Missing from our data, so excluded from this answer: positive EBIT.
Accruals are positive and DSO is up +128 days over 3 years — profit is being recognised ahead of collection.
Accruals are positive and DSO is up +128 days over 3 years. Either alone is explainable; together they are revenue recognised ahead of collection.
Missing from our data, so excluded from this answer: share_based_compensation.
Debt is present but there is no positive EBITDA or no reported interest expense, so coverage cannot be measured.
Balance sheet at 2025-09-30. Undrawn revolving credit is not shown: the tag is collected but not yet mapped through to the API.
No material counter-signal in the checked set: net debt / EBITDA, interest coverage, stressed coverage, maturity schedule vs cash and one year of FCF, liquidity ratios.
Missing from our data, so excluded from this answer: ebitda.
No growth rate within the range this model can express reaches the current price, so the requirement cannot be stated as a number.
No material counter-signal in the checked set: reverse-DCF implied growth, historical FCF CAGR, per-year FCF growth distribution, reporting-basis breaks, discount rate used, free-cash-flow basis (stock comp charged?).
Missing from our data, so excluded from this answer: implied_growth.
| Step | Amount | Running total |
|---|---|---|
| Net income | −$3.67B | −$3.67B |
| Share-based comp | not reported | not reported |
| Other non-cash & working capital | −$1.38B | −$5.05B |
| Operating cash flow | −$5.05B | −$5.05B |
| Capex | −$267M | −$5.32B |
| Free cash flow | −$5.32B | −$5.32B |
| Fiscal year | Revenue growth | Receivables growth | Gap |
|---|---|---|---|
| FY2020 | -7.6% | not reported | not reported |
| FY2021 | 56.3% | 43.3% | -13.0 points |
| FY2022 | -16.3% | -2.5% | 13.8 points |
| FY2023 | -19.5% | -27.5% | -7.9 points |
| FY2024 | 71163.9% | 117066.9% | 45903.0 points |
| FY2025 | -22.4% | 0.8% | 23.2 points |
| Fiscal year | DSO | DIO | DPO | Cash conversion cycle |
|---|---|---|---|---|
| FY2019 | not reported | not reported | not reported | not reported |
| FY2020 | 129.2 days | 41.9 days | 59.1 days | 112 days |
| FY2021 | 118.5 days | 39.7 days | 85.6 days | 72.6 days |
| FY2022 | 138.1 days | 44.1 days | 61.5 days | 120.7 days |
| FY2023 | 124.4 days | 0.1 days | 0.1 days | 124.4 days |
| FY2024 | 204.6 days | 37.4 days | 105.8 days | 136.2 days |
| FY2025 | 265.9 days | 69.3 days | 52.7 days | 282.4 days |
| Fiscal year | Accruals / assets |
|---|---|
| FY2019 | not reported |
| FY2020 | 5.0 percent |
| FY2021 | 19.1 percent |
| FY2022 | -11.1 percent |
| FY2023 | -2692.3 percent |
| FY2024 | 1.1 percent |
| FY2025 | 2.0 percent |
Below the line, the asset base is being consumed faster than it is replaced.
Below the line for 7 consecutive years to the latest.
Depreciation here includes amortisation of acquired intangibles — goodwill written down over time, customer lists, acquired technology. Capex does not replace those and is not meant to, so an acquisitive or asset-light company sits below 1.0 permanently and correctly. The signal is cleanest for capital-intensive businesses, where the two measure the same physical base. For that reason this informs the earnings-quality verdict but never caps it.